Research and Markets: FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Res

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ad354f/fda_approves_zytig) has announced the addition of GlobalData 's new report "FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer" to their offering.

FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer

It has been an exciting year for prostate cancer therapeutics. On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prostate cancer (CPRC) following failed Taxotere (docetaxel) therapy. This comes after the approval of three molecules for the treatment of prostate cancer in 2010, Jevtana (cabazitaxel) from Sanofi-Aventis, Provenge (sipuleucel-T, a cancer vaccine) and Xgeva (denosumab). These were the first molecules to gain approval since Taxotere, an anti-mitotic chemotherapy, in 2006.

Scope

Zytiga is produced by Centocor Ortho Biotech, a subsidiary of Johnson and Johnson (J&J). It is not considered to be chemotherapy but is instead a hormone treatment. In the body, Zytiga is converted into an androgen biosynthesis inhibitor that acts on 17 a-hydroxylase/C17,20-lyase (CYP17) and consequently reduces testosterone. Testosterone encourages the progression of prostate cancer. This is more comprehensive than other androgen-reducing therapies as it acts on the production of androgens in the testes, adrenal gland and the prostate tissue itself rather than just those produced in the testes.

Reasons to buy

Impact analysis of approval of Zytiga (Abiraterone Acetate)as a Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer

Key Topics Covered:

1 Tables of Contents

2 Summary

3 Prostate Cancer Overview

3.1 Disease Overview

3.2 Epidemiology

3.3 Current Therapy Options

3.4 Unmet Need

3.5 Drivers and Barriers

3.5.1 Drivers

3.5.2 Barriers

3.6 Zytiga

3.6.1 COU-AA-301 Clinical Trial Details

3.6.2 Dosage and Pricing of Zytiga

3.7 Prostate Cancer Market

4 Appendix

For more information visit http://www.researchandmarkets.com/research/ad354f/fda_approves_zytig



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.